hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 19:59:04 - browse：1

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

focus

WSS

In venture capital firm's success, lessons for turning crisis into profit

Lessons Learned: This is why you network to find that industry job you want

More regulation could be coming for drug ads

‘The Bear’ and hospitality in hospitals

HIV vaccine remains elusive. Immunologists keep trying new ideas

Biden praises World Series champion Astros for impact off the field during White House celebration

entertainment

hotspot

Wikipedia

Activists slam private health insurers over coverage restrictions

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

After affirmative action ruling, medical educators look to 'holistic review'

Helping hospitals and community health centers plan for resilience

In age of alternative facts, a scholarly course on calling out crap

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

State Dept. review finds Biden bears some blame for Afghanistan failures

Cytokinetics CEO stresses company can launch heart drug on its own

DIEP, the 'gold standard' of breast reconstruction, is under threat

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

entertainment

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Helping hospitals and community health centers plan for resilience

Judge rejects Trump's counterclaim against E. Jean Carroll

In venture capital firm's success, lessons for turning crisis into profit

Case highlights the risks of experimental stem cell therapy

Wegovy cuts risk of cardiovascular events by 20%, study finds

knowledge

Wikipedia

focus

knowledge